Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational CohortObservational Study Published on 2022-08-242022-10-04 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 임상, [키워드] Admission anticipated baseline benefit Clinical outcome Clinical practice Comparative comparative effectiveness research complement coronavirus disease COVID-19 Cox proportional hazard discharged Effectiveness examined excluded hazard ratio Hospital admission Hospitalization hospitalized COVID-19 patients hospitalized patient initiated invasive mechanical low-flow oxygen lower risk membrane Mortality outcome Oxygenation Patient patients patients died patients hospitalized patients with COVID-19 propensity score matching randomized trials RDV receiving reduction in mortality Remdesivir statistical significance supplemental oxygen Support survival treated Treatment unique Ventilation was used were used with COVID-19 [DOI] 10.1093/cid/ciab875 PMC 바로가기 [Article Type] Observational Study
A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load코로나19 고위험 보행 환자를 대상으로 한 밤라니비맙과 에테세비맙의 무작위 위약 대조 임상 시험 및 지속적으로 높은 바이러스 부하의 예후 가치 검증Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 임상, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age ambulatory ambulatory patient ambulatory patients antibody treatment applicability bamlanivimab baseline characterized clinical clinical status Cohort confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 test Day death determine etesevimab expand first positive greater high risk Hospitalization infused Interim analyses interim analysis intravenously investigated load lower dose median median age Mild-to-moderate NCT04427501 occurred optimal dose outcome Patient persistently high viral load. phase Placebo placebo group receiving reduction in respiratory risk factor SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 Support the placebo group These data those receiving placebo Treatment Trial validation value variant Viral Viral load [DOI] 10.1093/cid/ciab912 PMC 바로가기 [Article Type] Randomized Controlled Trial
Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant델타 변종에 대한 코로나바이러스 질병 2019(COVID-19) 백신의 비교 효과Comparative Study Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Against Analysis approved BNT162b2 Comparative comparative effectiveness contributed coronavirus coronavirus disease Coronavirus disease 2019 covariate COVID-19 COVID-19 hospitalization COVID-19 vaccine COVID-19 vaccines Cox model declined Delta delta variant effective Effectiveness Efficacy hazard ratio Healthcare system Hospitalization Immunity impacted Infection IPW Kaplan-Meier lack large cohort lower risk Medicine Moderna mRNA mRNA-1273 mRNA-1273 vaccine mRNA-based vaccine mRNA-based vaccines Patient Pfizer-BioNTech recipient recipients risk SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus significantly vaccination Vaccine variant waning immunity [DOI] 10.1093/cid/ciac106 PMC 바로가기 [Article Type] Comparative Study
Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 20212021년 8월까지 플로리다 메이요 클리닉에서 입원이 필요한 코로나바이러스 질병 2019 백신 혁신적 감염Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] Breakthrough infection breakthrough infections characterized Comorbidities coronavirus disease Coronavirus disease 2019 COVID-19 delta variant Hospitalization hospitalizations Mayo Clinic Older Patient preventive measure preventive measures single center vaccination Vaccine vaccine-breakthrough. variant [DOI] 10.1093/cid/ciab932 PMC 바로가기 [Article Type] Article
Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant코로나바이러스 질병 2019 오미크론 변이체에 감염된 어린이의 질병 심각도Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted odds ratio Admission age children Control coronavirus Coronavirus 2019 COVID-19 death Delta delta variant determined by Diagnosis disease disease severity Hospital admission Hospitalization ICU ICU care Infection intensive care intensive care unit less mechanical ventilation Mild moderate omicron Omicron variant outcome outcomes Primary outcome Propensity score SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe disease significantly lower variant [DOI] 10.1093/cid/ciac275 PMC 바로가기 [Article Type] Article
Pediatric Hospitalizations After School Reopening During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Alpha (B.1.1.7) Variant Spread: A Multicenter Cross-sectional Study in Israel중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 알파(B.1.1.7) 변종 확산 중 방과 후 소아과 재입원: 이스라엘의 다기관 횡단면 연구Multicenter Study Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha B.1.1.7 Child coronavirus coronavirus 2 cross-sectional cross-sectional study emergency department Evidence followed by Hospitalization hospitalizations increase in intensive care unit intensive care units morbidity multicenter opening pandemic pediatric provide reopening respiratory SARS-CoV-2 School severe acute respiratory syndrome Coronavirus Spread the SARS-CoV-2 variant [DOI] 10.1093/cid/ciac065 PMC 바로가기 [Article Type] Multicenter Study
Associations Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants and Risk of Coronavirus Disease 2019 (COVID-19) Hospitalization Among Confirmed Cases in Washington State: A Retrospective Cohort Study워싱턴 주에서 확인된 사례 중 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 변종과 코로나바이러스 질병 2019(COVID-19) 입원 위험 간의 연관성: 후향적 코호트 연구Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 age Alpha Analysis Beta Chain Reaction collected Confirmed coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 Cox proportional hazard Cox proportional hazards model Delta disease severity Effects Gamma genomic Genomic surveillance hazard ratio hazard ratios hospital Hospitalization Hospitalized include individual Infection Lineage no significant difference omicron pandemic Patient polymerase chain polymerase chain reaction positive proportional hazards model Reporting respiratory resulting retrospective cohort study reverse transcription reverse transcription polymerase chain reaction risk RT-PCR SARS-CoV-2 sequenced Sex specimen Support Surveillance System vaccination variant variants viral genome Washington [DOI] 10.1093/cid/ciac279 PMC 바로가기 [Article Type] Article
C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4dArticle Published on 2022-08-242022-11-15 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, [키워드] Activation Alternative pathway Analysis anaphylatoxin C4d C5a Clinical course clinical risk clinical risk score collected complement Complement pathway complement system convalescent correlation Course COVID-19 disease severity elevated evaluated Follow-up groups highest hospital discharge Hospitalization infected with SARS-CoV-2 marker Numerous pathway Patient positive correlation reported severe COVID-19 severely ill patient severity soluble fraction suffered the disease the patient upstream were assessed [DOI] 10.3389/fimmu.2022.946522 PMC 바로가기
Age-Specific Changes in Virulence Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 변종 우려와 관련된 병독성의 연령별 변화Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 치료기술, [키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjusted Admission age all age groups association Canada change children Comorbidity concern coronavirus coronavirus 2 death Delta VOC delta VoCs Elevation Epidemiology estimate evaluate Factor greater group Health health outcomes Hospitalization ICU ICU admission increase in increases in individual individuals Infection intensive care intensive care unit logistic regression model Model novel Older outcome positive respiratory retrospective cohort risk risk of death SARS Coronavirus SARS coronavirus-2 SARS-CoV-2 screened severe acute respiratory syndrome Coronavirus severity Sex tested vaccination Vaccination Status variables variants of concern virulence VoC VOCs [DOI] 10.1093/cid/ciac174 PMC 바로가기 [Article Type] Article
Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic reviewArticle Published on 2022-08-242022-11-16 Journal: Frontiers in Immunology [Category] SARS, 변종, [키워드] 95% CI acute respiratory syndrome Against approved booster booster dose booster vaccination characterized coronavirus coronavirus disease COVID-19 COVID-19 vaccine Critical death dominant variant Effectiveness estimate European evaluated Evidence Hospitalization ICU admission Immunity immunization indicated Infection interim analysis long-lasting Mild moderate omicron Omicron variant outcomes Participants performed PROTECT ranged receiving remained risk of bia robust SARS-CoV-2 SARS-COV-2 infection searched severe COVID-19 study heterogeneity symptomatic systematic review the SARS-CoV-2 union vaccination Vaccine vaccine effectiveness variant variant of concern website [DOI] 10.3389/fimmu.2022.940562 PMC 바로가기